[{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"}]

Find Gastroenterology Clinical Drug Pipeline Developments & Deals by Regeneron Pharmaceuticals

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of IL-4 and IL-13 for treating eosinophilic esophagitis.

                          Product Name : Dupixent

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 20, 2024

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Forum
                          Not Confirmed
                          Peptide Forum
                          Not Confirmed

                          Details : Dupixent (dupilumab) is a monoclonal antibody that inhibits IL-4 and IL-13 signaling, approved for children 1+ with eosinophilic esophagitis, and is not immunosuppressive.

                          Product Name : Dupixent

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 25, 2024

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13), and US FDA has accepted for Priority Review the sBLA for the treatment of children aged 1 to 11 years with eosin...

                          Product Name : Dupixent

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 26, 2023

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : Dupixent (dupilumab), which was invented using Regeneron's proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.

                          Product Name : Dupixent

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          December 21, 2022

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : Dupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Pha...

                          Product Name : Dupixent

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          December 16, 2022

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : Dupixent (dupilumab) is administered as an injection under the skin (subcutaneous injection) at different injection sites. With this approval, Dupixent becomes the first and only medicine specifically indicated to treat EoE in the United States.

                          Product Name : Dupixent

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 20, 2022

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : Dupixent demonstrated significant clinical and anatomic improvements, including the ability to swallow, in Part A of pivotal trial.

                          Product Name : Dupixent

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 22, 2020

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank